Hualien Tzu Chi Hospital has joined hands with Songji Biotech to initiate a clinical evaluation of collagen peptide nucleic acid for arthritis and skin aging. In August 2023, the collaboration agreement was signed by Hospital Superintendent Dr. Lin Hsin-Jung, Vice Superintendent Dr. Huang Chih-Yang, and Songji Biotech Chairman Chiu Yang-Hao.
According to the hospital, as people age, the renewal of epidermal and dermal cells slows down. Combined with oxidative stress from free radicals, this leads to the loss of collagen and elastin, causing wrinkles and joint degeneration. The study will employ collagen peptide nucleic acid with three key features—small molecular size, high purity, and stable structure—with the aim of slowing down aging and improving health.
Dr. Lin emphasized that delaying skin and joint aging is not only about appearance but also about maintaining quality of life. He expressed hope that the partnership will open new opportunities in anti-aging research and contribute to the well-being of the public.